Breast Cancer Research and Treatment This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Palliative care utilization and racial and ethnic disparities among women with de novo metastatic breast cancer in the United States
ConclusionsFewer than 25% of women with MBC received palliative care between 2010 and 2017. While palliative care has significantly increased for all racial/ethnic groups, Hispanic White, Black, and Asian/Pacific Islander women with MBC still receive significantly less palliative care than non-Hispanic White women. Further research is needed to identify the socioeconomic and cultural barriers to palliative care utilization. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 3, 2023 Category: Cancer & Oncology Source Type: research

PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients —a South African cohort study
ConclusionAggressive tumour biology was common in our cohort. HIV infection, PAM50 HER2-enriched,basal-like intrinsic subtypes and high ROR score were associated with poor overall and disease-free survival. HIV infection impacted survival in patients with luminal subtypes only. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 2, 2023 Category: Cancer & Oncology Source Type: research

Breast cancer treatment receipt and the role of financial stress, health literacy, and numeracy among diverse breast cancer survivors
ConclusionIn this diverse population of breast cancer survivors, rates of treatment initiation were high. Worry about paying medical bills and financial strain were frequent, especially among non-White participants. Although we observed associations of financial strain with treatment initiation, because few women declined treatments, understanding the scope of impact is limited. Our results highlight the importance of assessments of resource needs and allocation of support for breast cancer survivors. Novelty of this work includes the granular measures of financial strain and inclusion of health literacy and numeracy. (Sou...
Source: Breast Cancer Research and Treatment - May 28, 2023 Category: Cancer & Oncology Source Type: research

Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34
ConclusionsTogether, these findings from in vitro, ex vivo, and in vivo models show that SMIP34 may be a useful therapeutic agent for inhibiting PELP1 signaling in TNBC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 28, 2023 Category: Cancer & Oncology Source Type: research

Clinical significance of microinvasive breast cancer across the different subtypes and human epidermal growth factor receptor 2  expression levels
ConclusionHER2 overexpression was significantly associated with adverse clinicopathologic parameters and increased local recurrence risk in MiBC. Therefore, more understanding of the clinical behavior of HER2 in MiBC will enable tailoring of adjuvant therapy for these patients. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 28, 2023 Category: Cancer & Oncology Source Type: research

The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer
ConclusionsBlack women with EBC had significantly worse outcomes compared to White women in our cohort study. There is an urgent need to understand the disparities in outcomes between Black and White breast cancer patients, particularly in young women where the disparity in outcome is the greatest. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 28, 2023 Category: Cancer & Oncology Source Type: research

Correction to: Pathogenic variants among females with breast cancer and a non ‑breast cancer reveal opportunities for cancer interception
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 28, 2023 Category: Cancer & Oncology Source Type: research

Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis
ConclusionPatients with a poor PS, such as those described here, may still have meaningful clinical responses to cancer treatments targeting oncogenic drivers. More studies evaluating PARPi ’s beyondgBRCA1/2 mutations and in sub-optimal PS would help identify patients who may benefit from these therapies. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 12, 2023 Category: Cancer & Oncology Source Type: research

Impact of diabetes on surgery and radiotherapy for breast cancer
ConclusionsDiabetes is associated with a lower likelihood of receiving surgery and a greater delay to surgery. Women with diabetes are also less likely to have breast reconstruction after mastectomy. These differences need to be taken in to account when considering factors that may impact on the outcomes of women with diabetes especially for M āori, Pacific and Asian women. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 12, 2023 Category: Cancer & Oncology Source Type: research

Cholesterol and breast cancer risk: a cohort study using health insurance claims and health checkup databases
ConclusionIn this population, there was a modest association of LDL-C at the clinical cutoff values for diagnosing hyperlipidemia (140  mg/mL), and there were no associations of HDL-C and TG with breast cancer risk. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 12, 2023 Category: Cancer & Oncology Source Type: research

Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials
ConclusionIn this population of high-risk patients with localized HR  + /HER2- BC, the risk of ILR was low but remained constant over 10 years. Younger age at diagnosis, breast-conserving surgery, and adjuvant endocrine therapy were independent risk factors of ILR. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 12, 2023 Category: Cancer & Oncology Source Type: research

Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41
ConclusionsAlthough pCR, RFI, and OS were numerically better with the dual combination and less with L, the differences were not statistically significant. However, achievement of pCR again correlated with improved outcomes, especially remarkable in the ER-negative subset.Clinical trials registrationNCT00486668 (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 12, 2023 Category: Cancer & Oncology Source Type: research

Pharmacogenetics: uncovering the complex relationship between HIV and non-adherence among South African  breast cancer patients treated with tamoxifen
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 12, 2023 Category: Cancer & Oncology Source Type: research

Nuclear magnetic resonance-determined lipoprotein profile and risk of breast cancer: a Mendelian randomization study
ConclusionWe identified a heterogeneous effect of subclass HDLs and a consistent protective effect of VLDL on breast cancer. Only the effects of small HDL and VLDL on ER  + subtype remained robust after controlling for obesity. These findings provide new insight into the causal pathway underlying lipoproteins and breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 10, 2023 Category: Cancer & Oncology Source Type: research

The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer
ConclusionsMpBCs are associated with poorer prognoses than IDC-NSTs. They are heterogeneous with different clinicopathological features and clinical outcomes between histological subtypes. Pure and with heterologous mesenchymal differentiation subtypes have more survival benefits than the mixed subtype. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 9, 2023 Category: Cancer & Oncology Source Type: research